

CURRICULUM VITAE -- PRINCIPAL INVESTIGATOR

Name: Dr. David O'Connor
Credentials: MBBS, PhD, FRACP -- Medical Oncology
Institution: Sydney Cancer Center, University of Sydney
Role in Study: Principal Investigator -- NVX-1218.22
CV Date: 2024-03-01

Education & Training

Degree	Field	Institution	Year
MD	Medicine	University (Local)	1998-2004
PhD	Oncology	Graduate Institute	2004-2008
Residency	Internal Medicine	Teaching Hospital	2008-2011
Fellowship	Medical Oncology	Cancer Center	2011-2013

Current Appointments

Principal Investigator and Head of Medical Oncology, Sydney Cancer Center (2013-present)
Associate Professor, Oncology, affiliated university (2015-present)

GCP Training

Last GCP Training: 10 February 2024
Certificate Valid Until: 10 February 2026
Training Provider: Transcelerate BioPharma / CITI Program

Relevant Clinical Trial Experience

Principal Investigator on 12 Phase I-III oncology trials over 10 years, including 4 studies in NSCLC. Co-investigator on 6 additional studies. Enrolled >150 subjects across oncology trials. No serious protocol deviations in prior studies. Familiar with ICH GCP E6(R2) requirements.

Publications (Selected)

- David O'Connor et al. (2022). Novel immunotherapy approaches in advanced NSCLC. J Clin Oncol. 40(15):1623-1634.
- David O'Connor et al. (2020). Real-world outcomes in EGFR-mutated NSCLC. Lung Cancer. 142:45-52.
- David O'Connor et al. (2019). Biomarker-driven patient selection in oncology trials. Ann Oncol. 30(6):987-994.

I certify that the information in this CV is current and accurate:

Dr. David O'Connor

2024-03-01